Bioregulators & Organ Support
Crystagen
← Back to Library
Protocol not independently verified Immunity Bioregulator
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 20 mg
Dosing window: Bedtime (fasted)
Receptor / target: Immune System
Properties: Not stated
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 1mg 1x Daily at bedtime fasted | Standard Khavinson protocol. Repeat 3-4 times per year. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative Titration 1: Extended Protocol (Goal: sustained peripheral immune cell gene program normalization with minimized peak immune activation; preferred for sensitive subjects or first cycle)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-30 | 500mcg 1x Daily at bedtime fasted | Half-dose extended cycle. For subjects sensitive to immune activation symptoms (flu-like initiation response). Lower peak NK/T-cell activation with equivalent cumulative exposure. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 2: NK Cell Cancer Surveillance Protocol (Goal: maximize NK cell cytotoxic gene program restoration for subjects with elevated cancer risk, family history, or post-cancer surveillance; combine with Vilon for upstream thymic coverage)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-5 | 500mcg 1x Daily at bedtime fasted | Entry dose. Baseline CBC with lymphocyte differential before initiating. |
| Days 6-20 | 1mg 1x Daily at bedtime fasted | Full standard dose. Run concurrent with Vilon for thymic + peripheral immune combined protocol. |
| Days 21-30 | 500mcg 1x Daily at bedtime fasted | Taper phase. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 3: Pre/Post-Infection Immune Reinforcement Protocol (Goal: rapid NK cell and T-cell gene program activation before known infectious exposure (travel, procedure) or to accelerate immune recovery post-infection)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 (1-2 weeks before known exposure) | 1mg 1x Daily at bedtime fasted | Pre-exposure NK and T-cell priming. Particularly valuable before immunologically stressful events (international travel, elective surgery, vaccination). |
| Days 1-10 (immediately post-infection/post-acute phase) | 1mg 1x Daily at bedtime fasted | Post-infection recovery course. Normalize NK and T-cell gene programs depleted by acute infectious response. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 4: Vilon + Crystagen Complete Immune Rejuvenation Stack (Goal: full hierarchical immunosenescence reversal: thymic T-cell output (Vilon) + peripheral immune effector normalization (Crystagen); most complete anti-immunosenescence protocol in the database)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | Vilon 10mg 1x Daily (anytime) + Crystagen 1mg 1x Daily (bedtime fasted) | Run both standard courses concurrently. Most complete immune bioregulator protocol in the database. |
| Days 11-20 | Crystagen 1mg 1x Daily (bedtime fasted): Vilon taper optional | Extended Crystagen cycle after Vilon standard course completes. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 5: High-Frequency Quarterly Immune Maintenance Protocol (Goal: 4 cycles per year for subjects with significant immunosenescence, post-chemotherapy immune reconstruction, or chronic infection burden)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 (Q1) | 1mg 1x Daily at bedtime fasted | Cycle 1 (January). |
| Days 1-20 (Q2) | 1mg 1x Daily at bedtime fasted | Cycle 2 (April). |
| Days 1-20 (Q3) | 1mg 1x Daily at bedtime fasted | Cycle 3 (July). |
| Days 1-20 (Q4) | 1mg 1x Daily at bedtime fasted | Cycle 4 (October). Full annual peripheral immune coverage. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (Immune System); route Subcutaneous; timing Bedtime (fasted). Unapproved or source-dataset dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Active autoimmune disease: the broad and intense peripheral immune activation mechanism of Crystagen is directly contraindicated in any autoimmune condition where immune activation amplifies the self-reactive immune response; this includes rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, psoriasis, and other autoimmune conditions in active phase; this is the strictest autoimmune contraindication among the Khavinson immune bioregulators.
- Organ transplant recipients on immunosuppressive therapy: Crystagen's NK cell activation, T-cell normalization, and broad immune competence restoration directly opposes the immunosuppressive regimen required to prevent rejection; absolute contraindication.
- Concurrent biologic immunosuppressive therapy (TNF-alpha inhibitors, IL-6 inhibitors, IL-17 inhibitors, JAK inhibitors): Crystagen's immune activation mechanism conflicts with the intended immunosuppressive mechanism of these biologics.
- Active hematological malignancies involving lymphoid lineages (lymphoma, CLL, T-cell malignancies): NK cell activation, T-cell normalization, and B-cell stimulation in the context of malignant lymphoid clonal expansion requires oncological evaluation.
- Known hypersensitivity to Crystagen (Lys-Glu-Asp tripeptide) or formulation excipients.
- Active severe infection requiring antimicrobial management: Crystagen's immune activation during acute severe infection could dysregulate the already activated innate immune response.
- Pregnancy: broad immune system modulation during pregnancy, where maternal immune tolerance of the semi-allogeneic fetus is critically maintained, has not been evaluated and carries theoretical risks to the maternal-fetal immune interface.
- Pediatric subjects with normally functioning immune systems: intense immune bioregulator stimulation in subjects with fully competent immune function has no established therapeutic target and could produce immune hyperactivation.
- Immune checkpoint inhibitor therapy (pembrolizumab, nivolumab, ipilimumab) for oncological indications: concurrent NK/T-cell activation with checkpoint inhibitor-mediated T-cell unleashing could produce additive immune-related adverse events (irAE) of unpredictable severity.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Mild flu-like symptoms in first cycle days: the most commonly reported adverse effect; as NK cells, T-cells, and macrophages are activated and cytokine production normalizes, a transient systemic immune activation response manifests as mild fatigue, myalgia, and low-grade temperature elevation; typically resolves within 2-4 days as the immune normalization equilibrates.
- Mild lymph node awareness or tenderness: regional lymph node activation as lymphocyte proliferation and immune cell trafficking increases; benign; typically self-limiting within the first week.
- Mild fatigue: related to the metabolic demand of immune system activation; most pronounced in the first 3-5 days of a new cycle.
- Fasting requirement compliance challenge: unlike most Khavinson compounds, Crystagen requires a fasted state at bedtime; subjects who eat late or have acid reflux conditions that worsen with fasting may find this administration requirement difficult.
- Transient worsening of subclinical autoimmune manifestations: subjects with undiagnosed autoimmune predisposition may experience a mild flare of previously subclinical autoimmune symptoms as immune surveillance and reactivity are restored; warrants discontinuation and evaluation if it occurs.
- Mild skin changes: as NK cell and T-cell surveillance improves, some subjects with chronic viral skin manifestations (subclinical herpes, HPV-related) may notice transient flares as the immune system engages these previously tolerated infections more actively.
- Mild fever on initiation (rare): a small minority reports low-grade fever (< 38.0°C) in the first 1-2 days; a sign of immune activation rather than infection; resolves spontaneously without intervention.
- No serious immune adverse events documented in the Khavinson literature at standard protocol doses: Crystagen's safety profile in the aging and immunosenescence research cohorts is clean at standard doses; the most practically significant safety dimension is the autoimmune and transplant contraindication.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.